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The recommended drug for treating schistosomiasis is praziquantel 
(PZQ) at a dose of 40 mg/kg.[1] While 60 mg/kg has been used in 
some countries,[2] it has not been adopted for wide use in current 
schistosomiasis control programmes. In sub-Saharan Africa, which 
carries 90% of the global burden of schistosomiasis, PZQ has been 
used in mass drug administration,[3] resulting in a drastic decrease 
in morbidity and transmission of the disease. High cure rates (CRs) 
and satisfactory egg reduction rates (ERRs)[4-7] have been achieved in 
schoolchildren treated for schistosomiasis using a single or repeated 
dose of PZQ 40 mg/kg.
Although the 40 mg/kg body weight dose of PZQ reduces 
the schistosomiasis burden, cases of failure/resistance have been 
reported, prompting the possibility of using repeated doses. It was 
reported that repeating the standard dose of 40 mg/kg was more 
efficacious than a single dose,[8] although cases of failure were still 
observed.[9,10] Use of PZQ at 60 mg/kg body weight has therefore 
been suggested to prevent failure. Comparisons of the efficacy 
of PZQ given at the standard dose of 40 mg/kg v. 60 mg/kg as a 
split dose[11,12] have shown differing outcomes. Moreover, a study 
that compared the efficacy of a higher dose of PZQ (80 mg/kg) v. 
40  mg/kg found no difference between the doses.[13] For Schistosoma 
mansoni, both regimens had similar efficacy, although the 60 mg/kg 
dose was associated with more side-effects.[11] In contrast, improved 
efficacy was reported for the 60 mg/kg regimen compared with 
40 mg/kg. Factors such the parasite species,[8] parasite stage[14] 
and intensity of the infection affect PZQ treatment outcomes (CR 
and ERR). Low CRs have been reported for mixed infections of 
S. haematobium (37 - 93%) and S. mansoni (42 - 79%) with PZQ 
40 mg/kg.[8] PZQ does not kill immature worms,[15] and this has 
justified the use of a combination of PZQ with antimalarial drugs 
with anti-schistosoma properties such as artemether and artesunate 
to kill immature worms.[15,16] However, the outcomes of these trials 
have not been conclusive.
Since PZQ is the only drug recommended by the World Health 
Organization (WHO) for the treatment of schistosomiasis, it is crucial 
to monitor its efficacy constantly to prevent cases of treatment failure 
or eventual resistance. In sub-Saharan Africa, where S.  mansoni 
and S. haematobium are endemic,[17] investigations of the influence 
of genetic variations on the severity of S. haematobium infection 
reported conflicting results.[18,19]
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Background. The World Health Organization recommends praziquantel (PZQ) (40 mg/kg body weight) for treating schistosomiasis. 
However, drug failure has been reported, prompting use of 60 mg/kg, for which results have been inconsistent.
Objectives. To compare the efficacy of PZQ 40 mg/kg and 60 mg/kg in treating schoolchildren infected with Schistosoma haematobium.
Methods. The study was conducted during November 2017 - August 2018 in the Ingwavuma area, uMkhanyakude District, KwaZulu-
Natal Province, South Africa. Children aged 10 - 15 years were screened for S. haematobium using a filtration technique. Infected children 
were randomly assigned to a dose of PZQ of 40 mg/kg or 60 mg/kg. Side-effects were recorded within 24 hours after treatment using 
questionnaires and direct observation. Four weeks after treatment, participants were retested for S. haematobium infection. Baseline and 
post-treatment mean egg counts were calculated. Cure rate (CR) and egg reduction rate (ERR) were used to determine PZQ efficacy, while 
repeated-measures analysis of variance determined the effect of both doses on infection intensity. A χ2 test was used to determine the 
association of side-effects with treatment, with a p-value ≤0.05.
Results. Forty-three and 36 children were treated with PZQ 40 mg/kg and 60 mg/kg, respectively. The 40 mg/kg group had a CR of 79.0% 
and an ERR of 97.2%, and the 60 mg/kg group a CR of 83.0% and an ERR of 98.3%. The effect of dose on infection intensity was not 
significantly different between the two groups (p>0.05). Abdominal pains, dizziness and fatigue were common among children who received 
PZQ 40 mg/kg, while headache, dizziness and nausea were common in the 60 mg/kg group.
Conclusions. The efficacy of PZQ at 60 mg/kg was similar to that at 40 mg/kg. A dose >40 mg/kg therefore does not add value in treating 
S. haematobium infection. Transient side-effects (mostly dizziness) were observed more in the 60 mg/kg group than in the 40 mg/kg group. 
We recommend continued use of 40 mg/kg body weight for treating schistosomiasis.
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Objectives
Because of the lack of consensus on the efficacy of PZQ 40 mg/kg 
and 60 mg/kg in treating S. haematobium infection, we investigated 
the efficacy and evaluated the side-effects of PZQ at doses of 40 mg/
kg and 60 mg/kg among schoolchildren in the Ingwavuma area of 
uMkhanyakude District, KwaZulu-Natal Province, South Africa 
(SA), where schistosomiasis is endemic.[20]
Methods
Study area
The study was conducted in seven local primary schools from 
seven villages (Emunywana, Madeya intermediate, Maphindela, 
Mpolimpolini, Mugedula, Mbadleni and Ziposheni), located in the 
north-western part of the Ingwavuma area. The study area has a 
subtropical climate, characterised by erratic rainy and dry seasons, 
a hot and humid summer from November to February, and a cooler 
and drier winter from June to August.[21] The area also has limited 
sources of water, so the population relies on water bodies such as 
ephemeral rivers and ponds for their daily needs, as described in our 
previous study.[22] The study area experienced an extended period of 
drought from 2015 to 2017.[23]
Study design and sampling
A cohort of 10 - 15-year-old schoolchildren was recruited between 
November 2017 and March 2018 in seven schools (Emunywana, 
Madeya intermediate, Maphindela, Mpolimpolini, Mugedula, 
Mbadleni and Ziposheni) in the Ingwavuma area. Schools with 
a prevalence of S. haematobium infection of at least 30% based 
on our previous study[10] were purposefully selected. The study 
population for the targeted age group in the schools was 534 
after excluding children who had participated in previous surveys. 
Consent and assent forms were distributed to the 534 children, 
but only 442 brought signed forms back and hence became eligible 
to participate in the study. Eligible participants were screened for 
S.  haematobium using the urine filtration methods as described by 
Cheesbrough.[24] The 111 children found to be infected were divided 
into two groups based on infection intensity: a group with heavy 
infection and a group with light infection, in accordance with WHO 
classification.[25] Of the 111  infected children, 87 were treated and 
constituted our study cohort. Seventy-nine were successfully followed 
up and were included in the data analysis. Participants in each group 
were randomly assigned a PZQ dose of either 40 mg/kg (n=43 
participants) or 60 mg/kg (n=36). Treatment for the two groups was 
administered in June 2018 and follow-up screening was done after 
28 days (4 weeks). Eight infected children who were absent during 
the first round of treatment were treated in July during the follow-up 
and assessed in August 2018. For the assessment of side-effects, only 
54 participants responded successfully to the questionnaire. Those 
who were absent or could not provide urine samples 4 weeks after 
treatment were not included in the statistical analysis.
Data collection
Parasitology survey (collection of urine samples and processing)
Collection of urine samples for S. haematobium screening was 
done between 10h00 and 14h00, as recommended by the WHO.[25] 
Children were assigned an identification code by the research team 
members before being asked to provide a urine sample in a 90 mL 
plastic container labelled with a code. The containers were placed 
in a wooden box immediately after collection of the urine sample, 
and kept away from direct sunlight to avoid hatching of eggs. The 
urine samples were processed on the day of collection, using the 
recommended filtration technique.[24] Four weeks after treatment, 
the children were rescreened for S. haematobium infections, based 
on two urine samples collected on 2 consecutive days. Urine samples 
were collected and processed using the baseline technique to avoid 
any confounder effect on the post-treatment outcome.
PZQ treatment and post treatment monitoring
Before the start of the treatment process, a brief explanation about 
the side-effects of PZQ was given to participants by the research team 
nurse. Participants were also asked about any recent treatment they 
had taken. All infected children were weighed using a mechanical 
scale (786 seca, Germany) to determine weight for calculation of 
the treatment dose. They were given orange juice and four slices of 
bread spread with peanut butter before taking the drug. Treatment 
was administered in accordance with the dose (40 or 60 mg/kg body 
weight) for each randomised group. Treated children were observed 
for a minimum of 1 hour before being allowed to leave. Those who 
vomited after taking the drug were treated on the next visit to the area 
by the study team. All adverse events were recorded and appropriate 
care measures were taken. Twenty-four hours after treatment, a 
questionnaire related to any side-effects that had occurred since the 
treatment was administered using the KoBoCollect tool.[26]
Statistical analysis
Data were extracted from KoBoCollect[26] into an Excel spreadsheet, 
version 2016 (Microsoft, USA). Data analysis was done using Stata 
version 15 (StataCorp, USA). The means of egg counts were calculated 
at baseline (time 0) and at 4 weeks post treatment (time 1). For the 
assessment of PZQ efficacy, an average of egg counts for each child 
based on the urine samples collected on 2 consecutive days was 
calculated to represent the egg count after treatment (time 1). They 
were then log-transformed by adding 1 to allow the comparison of egg 
counts. Infection intensity was defined as ‘light’ for any number of eggs 
<50/10 mL of urine and ‘heavy’ for any number of eggs ≥50/10 mL. [27] 
Efficacy was defined as an absence of eggs in the urine specimen 
4 weeks (28 days) post treatment. To assess the efficacy of PZQ, CR 
and ERR were used and the following formulae were applied:[28]
CR = 
Number of negative children after treatment
Number of positive children before treatment
Arithmetical mean egg counts per 10 mL of urine after treatment 
Arithmetical mean egg counts per 10 mL of urine before treatment
 × 100
ERR =  (1 – ) × 100
Repeated-measures analysis of variance was used to determine the 
effect of both dosage and gender on the change in the intensity of 
infection between baseline and follow-up (4 weeks post treatment). 
Descriptive analysis was used to determine side-effects that were 
most frequent. Cross-tabulation was also done for both regimens 
and side-effects of PZQ. The χ2 test was used to determine the 
association of side-effects with the treatment regimen. A p-value 
≤0.05 was considered significant. Children who were treated but were 
absent during the assessment of efficacy or did not respond to the 
questionnaire related to side-effects were excluded from the analysis.
Ethical considerations
Ethical approval was sought and granted by the Biomedical 
Research Ethics Committee of the University of KwaZulu-Natal 
(ref. no. BE449/15). Gatekeeper permissions were obtained from the 
KwaZulu-Natal Department of Health, the traditional local leaders 
and local schools. Assent and consent were sought and obtained from 
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children and parents, respectively. Urine sample containers were 
coded for the purpose of confidentiality. All parents whose children 
were found to be infected were notified before treatment. At the time 
of writing, some of the participants had not been treated as they had 
moved from the area or changed schools.
Results
Infection patterns and efficacy of PZQ
Of the cohort of 87 infected children who were treated, 79 were 
successfully followed up. They provided two urine samples on 
2 consecutive days 4 weeks after treatment. Of the 79 participants, 64 
(81.0%) (38 female and 26 male) tested negative for S. haematobium 
and 15 (19.0%) (8 female and 7 male) tested positive, as shown in 
Table 1.
Of the 79 children who participated in the follow-up study, 43 
were treated with PZQ 40 mg/kg and 36 received 60 mg/kg. The 
CR and ERR were 79.0% and 97.2%, respectively, for children who 
received 40 mg/kg and 83.0% and 98.3%, respectively, for those who 
received 60 mg/kg (Table 1). The CR and ERR for the PZQ 60 mg/kg 
dose were slightly higher than for 40 mg/kg, but the difference was 
not statistically significant. In the children who tested positive for 
S. haematobium 4 weeks after the administration of PZQ, infection 
intensity was light. The effect of the dose on infection intensity (egg 
count) showed that there was no significant difference between 
treatment outcomes for PZQ 40 mg/kg and 60 mg/kg (p>0.05).
Side-effects after treatment with PZQ
Of the 79 children who were successfully followed up, 54 responded 
to questions related to side-effects. Side-effects ranged from headache, 
dizziness, abdominal cramps, nausea, vomiting, fatigue and sweating 
to muscle pain, the most frequent being dizziness (n=25; 46%), fatigue 
(n=20; 37.0%), headache (n=16; 29.6%), nausea (n=12, 22.2%) and 
abdominal pains (n=11; 20.4%). Based on the PZQ treatment regimen, 
abdominal pains, dizziness and fatigue were more prevalent among 
participants who received PZQ 40 mg/kg, while dizziness, headache 
and nausea were more prevalent among those who received 60 mg/kg 
(Table 2). Dizziness was the most prevalent side-effect in both groups.
Discussion
We investigated the effect of two doses of PZQ, 40 mg/kg and 60 mg/
kg, in schoolchildren. The CR and ERR were higher in the group 
that received PZQ at a dose of 60 mg/kg body weight than for the 
group treated with the same drug at 40 mg/kg. Nevertheless, the 
outcome indicates satisfactory efficacy of PZQ with both doses as 
per the WHO classification.[28] We did not establish any significant 
differences in the efficacy of the two doses. Our findings confirm 
those found in other efficacy studies.[2,11] Moreover, a study that 
compared higher doses of PZQ (50 mg/kg and 80 mg/kg) found 
similar results.[13] There are, however, other studies that used similar 
doses but reported lower cure rates against S. haematobium, and 
minor transient side-effects.[12,29] Efficacy of PZQ has been reported 
to increase with increased dose.[11] However, in another study testing 
escalating doses of PZQ (20 mg/kg, 40 mg/kg and 60 mg/kg), CR 
improved inversely to the dose.[30] A higher CR (85.7%) with PZQ 
20 mg/kg than 40 or 60 mg/kg was also reported by Coulibaly et 
al.[30] In line with the above, PZQ 40 mg/kg showed a higher CR 
than 60 mg/kg.[29] These results may suggest that a high dose of PZQ 
(60 mg/kg) has no additional benefit in treating schistosomiasis 
compared with 40 mg/kg. The infection intensity (number of eggs 
per 10 mL of urine) has been shown to influence treatment outcome. 
Higher CRs and more satisfactory ERRs have been reported among 
children with light infection intensity than among those with heavy 
infection,[31] contrary to what was reported in Uganda, where the CR 
was independent of infection intensity.[32]
We found that dizziness was the most frequent side-effect among 
children treated with PZQ 40 mg/kg body weight, followed by 
abdominal pains/cramps and fatigue. For the 60 mg/kg body weight 
dose, the most observed side-effects were dizziness and headache, 
followed by nausea. However, more children treated with 60 mg/
kg experienced dizziness compared with those who received 40 mg/
kg. Similar observations of side-effects at high doses of PZQ have 
been made in other studies,[11,33] but their specificity has not been 
determined. In another study, contrary to our findings, side-effects 
were not dose dependent.[12]
Conclusions
We found that use of PZQ at a dose of 60 mg/kg did not offer any 
advantage compared with the standard dose of 40 mg/kg in the 
treatment of S. haematobium infection. Although we observed 
transient side-effects for both doses, with dizziness being the most 
common, few severe side-effects were reported in the group treated 
with 60 mg/kg.
Table 1. CRs and ERRs at PZQ doses of 40 mg/kg and 60 mg/kg in children with Schistosoma haematobium infection
PZQ regimen
           Gender, n
Treated children, n Cured children, n CR, % ERR, %Female Male
40 mg/kg 25 18 43 34 79.0 97.2
60 mg/kg 12 15 36 30 83.0 98.3
CR = cure rate; ERR = egg reduction rate; PZQ = praziquantel.
Table 2. Post-treatment side-effects related to PZQ 40 mg/kg and 60 mg/kg
Side-effects
                                    Participants, n
χ2 p-valuePZQ 40 mg/kg (N=43) PZQ 60 mg/kg (N=36)
Headache 6 10 2.783 0.249
Dizziness 9 16 5.029 0.081
Fatigue 7 13 3.027 0.112
Abdominal pains 8 3 4.227 0.121
Nausea 4 8 3.078 0.215
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We therefore recommend that PZQ at the standard dose should be 
used for treatment of S. haematobium infection, as recommended 
by the WHO.[28] However, efficacy should be monitored continually 
for early detection of possible resistance of S. haematobium to PZQ.
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